Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.
| Revenue (TTM) | 31,000 |
| Gross Profit (TTM) | $-66.69M |
| EBITDA | $-98.63M |
| Operating Margin | -318494.00% |
| Return on Equity | -28.90% |
| Return on Assets | -17.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.44 |
| Price-to-Book | 1.21 |
| Price-to-Sales (TTM) | 18447.81 |
| EV/Revenue | 9115.92 |
| EV/EBITDA | 11.93 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 420.00% |
| Shares Outstanding | $194.52M |
| Float | $164.24M |
| % Insiders | 0.42% |
| % Institutions | 77.66% |
Volatility is currently contracting
Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
Altimmune NASDAQ: ALT said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD.
Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md.
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026.
Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes
Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder Transcript
Altimmune NASDAQ: ALT reported positive top-line results from its Phase II RECLAIM trial evaluating pemvidutide in adults with moderate to severe alcohol use disorder, or AUD, with the company saying the study met its primary endpoint and several secondary measures after 24 weeks of treatment.
Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, including two-level reduction in WHO risk drinking levels and zero heavy drinking days, both of which are recognized by the FDA as registrational endpoints A generally favorable tolerability profile was observed in the trial Conference call to be held today at 8:00 am ET GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on serious liver diseases, today announced positive topline results from the RECLAIM Phase 2 trial evaluating pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe alcohol use disorder (AUD).
Altimmune, Inc. is upgraded to Buy following successful fundraising, providing $535m to fund Phase 3 MASH trials through 2029. Pemvidutide's Phase 2b data showed statistically significant MASH resolution and fibrosis improvement, but competition from semaglutide, resmetirom, and others remains intense. ALT's near-term catalyst is the Phase 2 AUD data, with potential for partnership if results demonstrate differentiation in heavy drinking reduction and liver outcomes.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ALT and any ticker you trade — then tracks every position and per-strategy win rate.
